Drugs / Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02062359 | Feb 2014 → Feb 2016 | metastatic malignant neoplasm, metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02062359 ↗ |
| Modality | Cell therapy | “anti-ESO TCR gene-transduced CD62L+ -derived lymphocytes” NCT02062359 ↗ |
| Route | Intravenous | “cells (1x10e9 to 2x10e11) will be infused intravenously” NCT02062359 ↗ |